Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, a clinical-stage biopharmaceutical company developing drugs for the eye, announces positive preliminary Phase 2 results in patients with macular edema associated with RVO.